Page 87 - e-CPG-SLE-8_5_24

Management of Systemic Lupus Erythematosus

Appendix 8

FREQUENCY OF MONITORING PATIENTS WITH SLE
Patients with
active disease Patients with stable/
At first low disease activity
Assessments should be reviewed
visit should be reviewed
at least every every 6 - 12 months
1 - 3 months
Clinical
History   
Vital signs (blood   
pressure, heart rate,
weight)
Clinical examination   
Drug review   
Blood tests
Full blood count   
Renal profile   
Liver function test   
CRP   a  a
ESR   
Bone profile (calcium,  a  a  a
phosphate, ALP)
Vitamin D3  a -  a
Immunology/serology
ANA  - -
Anti-dsDNA   a  a
C3/C4 levels    a
aPL (LA, aCL, aβ2GPI)   a  a,p
ENA (anti-Ro/La, anti-RNP,   a  a,p
anti-Sm antibodies)
Immunoglobulin A, G, M  a  a  a
Direct Coombs’ test   a  a
Urine
UFEME   
Urine random protein:
creatinine ratio OR  a  a  a
24-hour urine protein
Other investigation
Culture  a  a  a
Biopsy (e.g. skin, kidney)  a  a  a
Neurophysiology (e.g.  a  a  a
nerve conduction study,
EMG)  a  a  a
ECG  a  a  a
Echocardiogram  a  a  a
Imaging
Chest X-ray  a  a  a
Others (US, CT, MRI)  a  a  a

70

Patients with
active disease Patients with stable/
At first low disease activity
Assessments should be reviewed
visit should be reviewed
at least every every 6 - 12 months
1 - 3 months
Modifiable cardiovascular
risk factors
Hypertension   
Dyslipidaemia   a  a
Diabetes mellitus   
High BMI   
Smoking/vaping   